NewsHK
New York-based Pomerantz LLP has filed a class action lawsuit against Immutep Limited, the Nasdaq-listed biopharmaceutical company trading under the ticker IMMP, the law firm announced on July 2, 2026.
Investors who have sustained losses on their Immutep holdings are being advised to contact the firm ahead of upcoming case deadlines.
Class Action Filed Against Nasdaq-Listed Immutep Pomerantz LLP, a plaintiff-side securities litigation firm operating out of New York, confirmed the filing of the class action against Immutep Limited.
The announcement was directed specifically at investors who have recorded losses on their positions in IMMP, urging them to come forward before designated deadlines pass.
Keep reading